1. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma.
- Author
-
Orenberg EK, Miller BH, Greenway HT, Koperski JA, Lowe N, Rosen T, Brown DM, Inui M, Korey AG, and Luck EE
- Subjects
- Adult, Aged, Carcinoma, Basal Cell pathology, Double-Blind Method, Drug Carriers, Drug Implants, Female, Fluorouracil adverse effects, Follow-Up Studies, Humans, Injections, Intralesional, Male, Middle Aged, Pilot Projects, Skin Neoplasms pathology, Carcinoma, Basal Cell drug therapy, Fluorouracil administration & dosage, Skin Neoplasms drug therapy
- Abstract
Background: Basal cell carcinomas (BCCs) are usually treated with ablative procedures. A nonsurgical treatment alternative would be of value in selected patients., Objective: We evaluated the safety and efficacy of a new preparation for intralesional sustained-release chemotherapy with MPI 5003, 5-Fluorouracil Therapeutic Implant, for treatment of BCCs., Methods: Two doses of intralesional MPI 5003 (0.25 and 0.5 ml) were compared in a double-blind study of 20 patients with biopsy-proven BCC. One BCC per patient was treated weekly for up to 6 weeks and followed up monthly for 3 months until excisional biopsy for histologic examination. Before excision the cosmetic appearance of the test site was graded., Results: Eighty percent of 10 BCCs treated with 0.5 ml of MPI 5003 had histologically confirmed cures as compared with 60% of 10 tumors treated with the lower dose (0.25 ml). Cosmetic assessments before excision were typically good to excellent. No systemic side effects occurred., Conclusion: Results indicate the potential of MPI 5003 for targeted local chemotherapy for BCC.
- Published
- 1992
- Full Text
- View/download PDF